Our laboratory recently correlated low levels of SPARC expression in colorectal cancers with decreased sensitivity to chemotherapy, and showed that reversal of therapy resistance could be achieved by upregulating SPARC expression or exogenous exposure to higher levels of SPARC either in vitro or in vivo (Tai et al, 2005). This evidence concerns the gene SPARC and colorectal cancer.